TruSight Oncology 500 High-ThroughputアッセイはTruSight Oncology 500アッセイをベースに、サンプルスループットとバッチオプションを向上させる柔軟性を備えています。
複数のバイオマーカーを一つのアッセイに統合
合理化されたサンプルからバリアントコールレポートまでのワークフロー
高いサンプルスループット
高い信頼性の結果を達成
施設内での包括的ゲノムプロファイリングの実現
このファミリーに含まれる3つのアッセイはすべて、主要ガイドラインや臨床試験に含まれる重要なバイオマーカーを検出するように設計されています。
FFPE検体から関連がんバイオマーカーを解析できます
TruSight Oncology 500アッセイ同様、組織検体から同じバイオマーカーを検出し、一回192サンプルまで解析できます
血漿検体から血中ctDNAを対象に、TruSight Oncology 500アッセイのDNAパネルと同じ遺伝子を解析します
TruSight Oncology 500 High-Throughput | TruSight Oncology 500 | TruSight Oncology 500 ctDNA | |
---|---|---|---|
Cancer Type | Pan-Cancer | Pan-Cancer | Pan-Cancer |
Content Specifications | Targeted selection of DNA from 523 genes of interest, and RNA from 55
genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*. |
Targeted selection of DNA from 523 genes of interest, and RNA from 55
genes, for a total of 1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Clinical Trials Coverage: Over 1,000 clinical trials • Immuno-oncology Biomarker Coverage: Biomarkers TMB and MSI included; also inclusive of HLA regions, POLE1 and POLD1*. |
Targeted selection of 523 genes (full coding sequence) for a total of
1.94Mb panel size. • Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types • Immuno-oncology Biomarker Coverage: TMB and MSI* |
Hands-On Time | ~10.5 hours | ~10.5 hours | ~10.5 hours |
Input Quantity | 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue) | 40 ng DNA, 40 ng RNA | 30 ng cfDNA (8-10 ml of plasma) |
Method | Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing | Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing | Target Enrichment , Target Enrichment, Targeted DNA Sequencing |
Nucleic Acid Type | DNA, RNA | DNA, RNA | DNA |
Sample Throughput | 16–192 samples per flow cell | ||
Specialized Sample Types | FFPE Tissue | FFPE Tissue | Blood, Cell-Free DNA |
Species Category | Human | Human | Human |
System Compatibility | NovaSeq 6000 | NextSeq 500 , NextSeq 550 , NextSeq 550Dx in Research Mode | NovaSeq 6000 |
Technology | Sequencing | Sequencing | Sequencing |
Variant Class | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Transcript Variants | Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Somatic Variants |
Optimizing RNA input to detect gene fusions with TruSight Oncology 500 High-Throughput
Technical Note | PDF< 1 MB
Simplifying the process to identify applicable variants in oncology samples
Brochure | PDF3 MB
Data Sheet | PDF | 4 versions
TruSight Oncology 500 High Throughput Consumables & Equipment Documentation
TruSight Oncology 500 High Throughput Checklist Documentation
TruSight Oncology 500 High Throughput Reference Guide Documentation
カスタムプロトコルセレクタ
Generates customized, end-to-end instructions
* Based on PierianDx Clinical knowledgebase, as of March 2020